These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 19192672)
1. Role of neoadjuvant treatment in cT3N0M0 rectal cancer. Pasetto LM; Friso ML; Pucciarelli S; Basso U; Rugge M; Sinigaglia G; Rossi E; Compostella A; Toppan P; Agostini M; Monfardini S Anticancer Res; 2008; 28(6B):4129-35. PubMed ID: 19192672 [TBL] [Abstract][Full Text] [Related]
2. Rectal cancer adjuvant chemotherapy: when is more useful? Pasetto LM; Basso U; Sinigaglia G; Pucciarelli S; Friso ML; Rugge M; Toppan P; Agostini M; Monfardini S Anticancer Res; 2008; 28(3B):1805-12. PubMed ID: 18630464 [TBL] [Abstract][Full Text] [Related]
3. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer. Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339 [TBL] [Abstract][Full Text] [Related]
5. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523 [TBL] [Abstract][Full Text] [Related]
6. Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis. Pasetto LM; Friso ML; Pucciarelli S; Basso U; Toppan P; Rugge M; Sinigaglia G; Nitti D; Sotti G; Monfardini S Anticancer Res; 2007; 27(2):1079-85. PubMed ID: 17465247 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023 [TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. ; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336 [TBL] [Abstract][Full Text] [Related]
9. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731 [TBL] [Abstract][Full Text] [Related]
10. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose. Lee SH; Lee KC; Choi JH; Oh JH; Baek JH; Park SH; Shin DB Jpn J Clin Oncol; 2008 Feb; 38(2):112-21. PubMed ID: 18263881 [TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report. Cafiero F; Gipponi M; Lionetto R; J Surg Oncol; 2003 Jul; 83(3):140-6. PubMed ID: 12827681 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720 [TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576 [TBL] [Abstract][Full Text] [Related]
14. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174 [TBL] [Abstract][Full Text] [Related]
16. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study. Caravatta L; Padula GD; Picardi V; Macchia G; Deodato F; Massaccesi M; Sofo L; Pacelli F; Rotondi F; Cecere G; Sallustio G; Di Lullo L; Piscopo A; Mignogna S; Bonomo P; Cellini N; Valentini V; Morganti AG Acta Oncol; 2011 Nov; 50(8):1151-7. PubMed ID: 21851185 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. Fakih MG; Bullarddunn K; Yang GY; Pendyala L; Toth K; Andrews C; Rustum YM; Ross ME; Levea C; Puthillath A; Park YM; Rajput A Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):650-7. PubMed ID: 18565686 [TBL] [Abstract][Full Text] [Related]
18. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. O'Connell MJ; Colangelo LH; Beart RW; Petrelli NJ; Allegra CJ; Sharif S; Pitot HC; Shields AF; Landry JC; Ryan DP; Parda DS; Mohiuddin M; Arora A; Evans LS; Bahary N; Soori GS; Eakle J; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Wozniak TF; Roh MS; Yothers G; Wolmark N J Clin Oncol; 2014 Jun; 32(18):1927-34. PubMed ID: 24799484 [TBL] [Abstract][Full Text] [Related]
19. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen. Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506 [TBL] [Abstract][Full Text] [Related]
20. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer. Moureau-Zabotto L; Farnault B; de Chaisemartin C; Esterni B; Lelong B; Viret F; Giovannini M; Monges G; Delpero JR; Bories E; Turrini O; Viens P; Salem N Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):483-91. PubMed ID: 21093174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]